Individualizing FcRn-Targeted Therapy and Earlier Treatment in MG

This episode, titled ‘Individualizing FcRn-Targeted Therapy and Earlier Treatment in MG,’ features panelists discussing how patient priorities influence both treatment goals and the timing of FcRn-targeted therapy. The experts emphasize that shared decision-making requires clinicians to understand the patient's dominant treatment priority and to reassess those priorities as the disease course evolves. Symptoms that may appear relatively mild from a clinical perspective can still meaningfully affect work, independence, and quality of life, making patient-defined goals central to evaluating whether control is adequate.

The faculty discuss how different priorities may lead to different treatment choices. A need for rapid improvement, a desire to reduce corticosteroid exposure, comorbidities, vaccination feasibility, and practical access to treatment can all influence which therapeutic approach is selected. These considerations become particularly important when deciding whether an FcRn-targeted therapy should be introduced earlier.

The panel then examines the potential role of FcRn inhibitors as a first advanced therapy. Conventional treatments and lower-dose corticosteroids remain effective for many patients, but experts describe situations in which severe manifestations, frequent rescue-therapy requirements, diabetes, renal concerns, or other treatment-limiting comorbidities may support earlier FcRn use. Faculty also highlight the real-world importance of access and the time needed to initiate targeted therapy. Ultimately, the panel supports a more individualized approach in which earlier effective control may help patients regain meaningful function rather than simply avoid severe exacerbations.

In the next episode, ‘Escalating Beyond Corticosteroids in Ocular and Lower-Burden MG,’ panelists will discuss when persistent symptoms or corticosteroid burden justify moving beyond conventional therapy and how functional impact can influence the urgency of escalation.